In8Bio (INAB) Stock News

IN8bio (Nasdaq: INAB) reported Q3 2025 results and program updates on Nov 6, 2025. The company presented new preclinical data on INB-619 showing CD19-targeted γδ T cell engager potency comparable to FDA-approved CD19/CD20 engagers with minimal cytokine release, and advanced its γδ T cell platform.

IN8bio expanded the Phase 1 INB-100 trial to The Ohio State University to accelerate enrollment and plans updated INB-200/400 GBM data at SNO (Nov 19-23, 2025) and additional INB-619 preclinical data at ASH (Dec 6-9, 2025).

Q3 financials: R&D $2.1M, G&A $1.9M, net loss $3.9M (‑$0.85/share), and cash $10.7M as of Sep 30, 2025.

IN8bio (Nasdaq: INAB) announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients receiving haploidentical stem cell transplants for leukemia.

The company said the addition aims to accelerate enrollment of the expansion cohort and deliver follow-up data next year. IN8bio noted clinical observations including long-term leukemic remissions beyond four and five years in earliest-treated patients, persistence and expansion of INB-100 up to 1 year, and an absence of severe graft-versus-host disease in presented data. Trial identifier: NCT03533816.

IN8bio (Nasdaq: INAB) on Oct. 27, 2025 presented preclinical data for INB-619, a pan-γδ T cell engager targeting CD19 for autoimmune disease. In SLE donor models INB-619 achieved complete B cell elimination with efficacy described as equivalent to approved engagers blinatumomab and mosunetuzumab, while producing markedly lower IL-6 and other cytokines. INB-619 expanded both Vδ1+ and Vδ2+ γδ T cell subsets and did not activate CD4+ or CD8+ αβ T cells in these assays. Data were presented at the 2025 ACR Convergence Meeting and are preclinical, indicating potential for deeper B cell depletion with a cytokine-sparing profile.

IN8bio (Nasdaq: INAB) reported significant clinical progress and financial results for Q2 2025. The company achieved a remarkable milestone in its INB-200 glioblastoma trial, with one patient surpassing four years without progression. Clinical data presented at ASCO 2025 showed patients receiving multiple doses achieved median progression-free survival of 16.1 months, more than double the standard-of-care outcome.

The company received recognition for its DeltEx™ manufacturing platform and presented promising preclinical data for INB-619, a gamma-delta T cell engager showing potential in lupus treatment. Financial results showed R&D expenses of $2.5M and G&A expenses of $2.7M, with a cash position of $13.2M extending runway into June 2026.

IN8bio announced a significant milestone in their Phase 1 trial of INB-200 gamma-delta T cell therapy for glioblastoma (GBM). A patient with grade 4, IDH-mutant glioma has achieved 4 years of remission and survival, maintaining good quality of life and returning to work. The Phase 1 trial data presented at ASCO 2025 showed INB-200's median progression-free survival (mPFS) of 16.1 months, more than double the 6.9 months typically seen with standard treatment. INB-200, the first genetically modified gamma-delta T cell therapy for GBM, has demonstrated a favorable safety profile and potential long-term benefits, marking a potential breakthrough in GBM treatment where standard care hasn't improved beyond 14-16 months overall survival in over 20 years.

IN8bio (NASDAQ: INAB) announced positive Phase 1 trial results for INB-200, their gamma-delta T cell therapy for newly diagnosed glioblastoma multiforme (GBM). The therapy demonstrated a median progression-free survival of 16.1 months in patients receiving multiple doses, more than double the 6.9 months typically observed with standard-of-care Stupp protocol. Four patients (40%) receiving repeated doses remain alive and progression-free for over two years, with three returning to work. The treatment showed favorable safety profile with no serious toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome. The company's Drug Resistant Immunotherapy (DRI) uses genetically modified gamma-delta T cells delivered directly into the brain in combination with standard maintenance chemotherapy. Preliminary Phase 2 trial data for INB-400 also shows promising results with mPFS at 10.8 months.

IN8bio (INAB) presented new preclinical data for INB-619, their gamma-delta T cell engager (TCE) therapy, at the ASGCT 2025 Annual Meeting. INB-619 demonstrated complete elimination of disease-causing B cells in blood samples from Systemic Lupus Erythematosus patients. The therapy successfully targets CD19+ B cells while expanding both Vδ1+ and Vδ2+ gamma-delta T cells.

Key advantages of INB-619 include its ability to deplete harmful IgG1 and IgM antibodies and achieve B cell elimination without triggering severe inflammatory responses like cytokine release syndrome (CRS). Unlike traditional CD3-based TCEs, the platform shows potential for safer and more precise immunotherapy for autoimmune diseases.

The company is exploring partnerships and additional indications where gamma-delta T cell biology and B cell targeting intersect.

IN8bio (NASDAQ: INAB) presented new data on its proprietary gamma-delta (γδ) T cell manufacturing program at ISCT 2025, receiving the Host Region Abstract Award. The company's DeltEx™ Allo manufacturing process demonstrated consistent production of potent cellular therapies for cancer treatment.

Key findings from the INB-100 study revealed: (1) Successful TCR reprogramming from αβ to γδ across all clinical batches, (2) High expression of cancer-killing and immune activation genes, and (3) Remarkable clinical outcomes with all 10 initial cohort patients remaining relapse-free for over a year, achieving a median overall survival of 23.3 months as of January 2024.

The company has automated its manufacturing program for rapid, reproducible production of cryopreserved cell therapy doses. The INB-100 trial is currently enrolling an expansion cohort at the recommended Phase 2 dose.

IN8bio (NASDAQ: INAB) reported significant progress in Q1 2025 with promising clinical results across its gamma-delta T cell therapy pipeline. The company's Phase 1 trial of INB-100 showed remarkable outcomes for Acute Myeloid Leukemia (AML) patients, with 100% remaining relapse-free after a median follow-up of 20.1 months. The therapy demonstrated impressive 1-year survival rates, with 90.9% progression-free survival and 100% overall survival. IN8bio also presented new data on their INB-600 T cell engager platform at AACR 2025, showing potential applications in both oncology and autoimmune diseases. Financially, the company raised $4.1 million through ATM sales and warrant exercises in Q1, ending the quarter with $11.9 million in cash. The company reported a net loss of $5.6 million ($0.07 per share), an improvement from the $8.6 million loss in the prior year period.